SlideShare a Scribd company logo
The Kit Yamoyo trial
Headline findings
from the Kit Yamoyo trial
Sep-12 to Aug-13
14The perception of
ORS as an
effective
treatment for
diarrhoea
increased by 14
percentage
points.
>26k
kits sold into the
two remote rural
trial areas in
12 months.
45%of children in trial
areas received
ORS/Zinc. Up
from a baseline
of <1%.
Comparator sites
stayed at <1%.
(OR 20.4, p<0.001)
2.4km
The distance to
ORS/Zinc in the
trial areas was
reduced by two-
thirds from
7.3km to 2.4km.
(p<0.001)
93%of Kit Yamoyo
users mixed ORS
correctly. Only
60% do when
given 1 litre
sachets.
(OR 1.84, p<0.05)
The Mapilelo Clinic in
Kalabo is a Kit Yamoyo
wholesaler and retailer
The Kit Yamoyo assembly team at Pharmanova
Tonight’s beer and soft drinks have been provided
courtesy of Zambian Breweries part of the SABMiller
Group.
SABMiller were partners in the Kit Yamoyo trial providing:
• Advice of value chain creation
• Funding and meeting facilities
Kit Yamoyo assembly at Pharmanova
Medical Stores Limited
are distributing a
GRZ version of
the Kit Yamoyo
Medical Stores Limited
will advertise
Kit Yamoyo on
their vehicles
200ml sachets of ORS – made in Zambia
• No wastage
• Less risk of contamination
Pediatric dispersible Zinc – made in Zambia
The Kit Yamoyo Flexi-pack
The Kit Yamoyo Flexi-pack measures the water needed to mix
the ORS correctly
The Screw-top version of
Kit Yamoyo is coming
soon!
Made in Zambia
Progress towards national scale-up
Trial – Sep-12 to Sep-13
Intervention districts
Progress towards national scale-up
Control districts
Trial – Sep-12 to Sep-13
Intervention districts
Progress towards national scale-up
Control districts
Trial – Sep-12 to Sep-13
Transition – from Oct-13
Transition districts
Intervention districts
Progress towards national scale-up
Control districts
Trial – Sep-12 to Sep-13
Transition – from Oct-13
Transition districts
Intervention districts
Activity in Southern Province stopped in
Nov-14 due to a lack of funding. We plan
to re-start marketing in early 2016.
Progress towards national scale-up
Scale-up
Control districts
Trial – Sep-12 to Sep-13
Transition – from Oct-13
Transition districts
Intervention districts
KYTS-ACE – from Feb-15
Activity in Southern Province stopped in
Nov-14 due to a lack of funding. We plan
to re-start marketing in early 2016.
Progress towards national scale-up
Activity in Southern Province stopped in
Nov-14 due to a lack of funding. We plan
to re-start marketing in early 2016.
Scale-up
Control districts
KYTS-LUSAKA – from Oct-15
Trial – Sep-12 to Sep-13
Transition – from Oct-13
Transition districts
Intervention districts
KYTS-ACE – from Feb-15
Scale-up
Control districts
KYTS-LUSAKA – from Oct-15
Trial – Sep-12 to Sep-13
Transition – from Oct-13
Transition districts
Intervention districts
KYTS-ACE – from Feb-15
Progress towards national scale-up
KYTS-SHOPRITE – from Dec-15
Activity in Southern Province stopped in
Nov-14 due to a lack of funding. We plan
to re-start marketing in early 2016.
Tonight’s beer and soft drinks have been provided
courtesy of Zambian Breweries part of the SABMiller
Group.
SABMiller were partners in the Kit Yamoyo trial providing:
• Advice of value chain creation
• Funding and meeting facilities
Thank you to the Kit Yamoyo funders
Isenberg Family
Charitable Foundation

More Related Content

More from ColaLife

The role of innovation in augmenting healthcare - the ColaLife Story
The role of innovation in augmenting healthcare - the ColaLife StoryThe role of innovation in augmenting healthcare - the ColaLife Story
The role of innovation in augmenting healthcare - the ColaLife Story
ColaLife
 
Designing for global health - Royal Society of Medicine
Designing for global health - Royal Society of MedicineDesigning for global health - Royal Society of Medicine
Designing for global health - Royal Society of Medicine
ColaLife
 
KYTS Programme Final Steering & Learning Group meeting 6-Sep-18
KYTS Programme Final Steering & Learning Group meeting 6-Sep-18KYTS Programme Final Steering & Learning Group meeting 6-Sep-18
KYTS Programme Final Steering & Learning Group meeting 6-Sep-18
ColaLife
 
Considerations in Last Mile Delivery in Access to Medicines – the ColaLife Story
Considerations in Last Mile Delivery in Access to Medicines – the ColaLife StoryConsiderations in Last Mile Delivery in Access to Medicines – the ColaLife Story
Considerations in Last Mile Delivery in Access to Medicines – the ColaLife Story
ColaLife
 
ColaLife - Cross-sector partnerships - new paradigms
ColaLife - Cross-sector partnerships - new paradigmsColaLife - Cross-sector partnerships - new paradigms
ColaLife - Cross-sector partnerships - new paradigms
ColaLife
 
KYTS Briefing - Collaboration Partners' meeting 20-Oct-15, Lusaka, Zambia
KYTS Briefing - Collaboration Partners' meeting 20-Oct-15, Lusaka, ZambiaKYTS Briefing - Collaboration Partners' meeting 20-Oct-15, Lusaka, Zambia
KYTS Briefing - Collaboration Partners' meeting 20-Oct-15, Lusaka, Zambia
ColaLife
 
Royal Society of Medicine - Medical Innovations - Kit Yamoyo and its value chain
Royal Society of Medicine - Medical Innovations - Kit Yamoyo and its value chainRoyal Society of Medicine - Medical Innovations - Kit Yamoyo and its value chain
Royal Society of Medicine - Medical Innovations - Kit Yamoyo and its value chain
ColaLife
 
ColaLife Presentation to the Janssen Management Board, 26-Aug-15
ColaLife Presentation to the Janssen Management Board, 26-Aug-15ColaLife Presentation to the Janssen Management Board, 26-Aug-15
ColaLife Presentation to the Janssen Management Board, 26-Aug-15
ColaLife
 
ColaLife Townhall Presentation, Janssen, Beerse, Belgium, 26-Aug-15
ColaLife Townhall Presentation, Janssen, Beerse, Belgium, 26-Aug-15ColaLife Townhall Presentation, Janssen, Beerse, Belgium, 26-Aug-15
ColaLife Townhall Presentation, Janssen, Beerse, Belgium, 26-Aug-15
ColaLife
 
ColaLife presentation to the ANDi Workshop, Addis Ababa, Jan-15
ColaLife presentation to the ANDi Workshop, Addis Ababa, Jan-15ColaLife presentation to the ANDi Workshop, Addis Ababa, Jan-15
ColaLife presentation to the ANDi Workshop, Addis Ababa, Jan-15
ColaLife
 
Zambia DHS 2014 - preliminary slides (22sept2014)
Zambia DHS 2014 - preliminary slides (22sept2014)Zambia DHS 2014 - preliminary slides (22sept2014)
Zambia DHS 2014 - preliminary slides (22sept2014)
ColaLife
 
The Kit Yamoyo Design Review
The Kit Yamoyo Design ReviewThe Kit Yamoyo Design Review
The Kit Yamoyo Design Review
ColaLife
 
Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14
Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14
Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14
ColaLife
 
Presentation to University of Michigan | 19-May-14
Presentation to University of Michigan | 19-May-14Presentation to University of Michigan | 19-May-14
Presentation to University of Michigan | 19-May-14
ColaLife
 
DuPont packaging awards May 2014
DuPont packaging awards May 2014DuPont packaging awards May 2014
DuPont packaging awards May 2014
ColaLife
 
ColaLife presention to C2MTL | 28-May-2014
ColaLife presention to C2MTL | 28-May-2014ColaLife presention to C2MTL | 28-May-2014
ColaLife presention to C2MTL | 28-May-2014
ColaLife
 
What we've learnt from Coca-Cola | Taking ColaLife to scale in Zambia
What we've learnt from Coca-Cola | Taking ColaLife to scale in ZambiaWhat we've learnt from Coca-Cola | Taking ColaLife to scale in Zambia
What we've learnt from Coca-Cola | Taking ColaLife to scale in Zambia
ColaLife
 
ColaLife | Key milestones - 1985 to Dec-13
ColaLife | Key milestones - 1985 to Dec-13ColaLife | Key milestones - 1985 to Dec-13
ColaLife | Key milestones - 1985 to Dec-13
ColaLife
 
ColaLife and frugal innovation 18-Sep-13
ColaLife and frugal innovation 18-Sep-13ColaLife and frugal innovation 18-Sep-13
ColaLife and frugal innovation 18-Sep-13
ColaLife
 
Presentation to the International Society for Neglected Tropical Diseases - 1...
Presentation to the International Society for Neglected Tropical Diseases - 1...Presentation to the International Society for Neglected Tropical Diseases - 1...
Presentation to the International Society for Neglected Tropical Diseases - 1...
ColaLife
 

More from ColaLife (20)

The role of innovation in augmenting healthcare - the ColaLife Story
The role of innovation in augmenting healthcare - the ColaLife StoryThe role of innovation in augmenting healthcare - the ColaLife Story
The role of innovation in augmenting healthcare - the ColaLife Story
 
Designing for global health - Royal Society of Medicine
Designing for global health - Royal Society of MedicineDesigning for global health - Royal Society of Medicine
Designing for global health - Royal Society of Medicine
 
KYTS Programme Final Steering & Learning Group meeting 6-Sep-18
KYTS Programme Final Steering & Learning Group meeting 6-Sep-18KYTS Programme Final Steering & Learning Group meeting 6-Sep-18
KYTS Programme Final Steering & Learning Group meeting 6-Sep-18
 
Considerations in Last Mile Delivery in Access to Medicines – the ColaLife Story
Considerations in Last Mile Delivery in Access to Medicines – the ColaLife StoryConsiderations in Last Mile Delivery in Access to Medicines – the ColaLife Story
Considerations in Last Mile Delivery in Access to Medicines – the ColaLife Story
 
ColaLife - Cross-sector partnerships - new paradigms
ColaLife - Cross-sector partnerships - new paradigmsColaLife - Cross-sector partnerships - new paradigms
ColaLife - Cross-sector partnerships - new paradigms
 
KYTS Briefing - Collaboration Partners' meeting 20-Oct-15, Lusaka, Zambia
KYTS Briefing - Collaboration Partners' meeting 20-Oct-15, Lusaka, ZambiaKYTS Briefing - Collaboration Partners' meeting 20-Oct-15, Lusaka, Zambia
KYTS Briefing - Collaboration Partners' meeting 20-Oct-15, Lusaka, Zambia
 
Royal Society of Medicine - Medical Innovations - Kit Yamoyo and its value chain
Royal Society of Medicine - Medical Innovations - Kit Yamoyo and its value chainRoyal Society of Medicine - Medical Innovations - Kit Yamoyo and its value chain
Royal Society of Medicine - Medical Innovations - Kit Yamoyo and its value chain
 
ColaLife Presentation to the Janssen Management Board, 26-Aug-15
ColaLife Presentation to the Janssen Management Board, 26-Aug-15ColaLife Presentation to the Janssen Management Board, 26-Aug-15
ColaLife Presentation to the Janssen Management Board, 26-Aug-15
 
ColaLife Townhall Presentation, Janssen, Beerse, Belgium, 26-Aug-15
ColaLife Townhall Presentation, Janssen, Beerse, Belgium, 26-Aug-15ColaLife Townhall Presentation, Janssen, Beerse, Belgium, 26-Aug-15
ColaLife Townhall Presentation, Janssen, Beerse, Belgium, 26-Aug-15
 
ColaLife presentation to the ANDi Workshop, Addis Ababa, Jan-15
ColaLife presentation to the ANDi Workshop, Addis Ababa, Jan-15ColaLife presentation to the ANDi Workshop, Addis Ababa, Jan-15
ColaLife presentation to the ANDi Workshop, Addis Ababa, Jan-15
 
Zambia DHS 2014 - preliminary slides (22sept2014)
Zambia DHS 2014 - preliminary slides (22sept2014)Zambia DHS 2014 - preliminary slides (22sept2014)
Zambia DHS 2014 - preliminary slides (22sept2014)
 
The Kit Yamoyo Design Review
The Kit Yamoyo Design ReviewThe Kit Yamoyo Design Review
The Kit Yamoyo Design Review
 
Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14
Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14
Presentation to PATH (Seattle, Washington DC and San Francisco), 23-May-14
 
Presentation to University of Michigan | 19-May-14
Presentation to University of Michigan | 19-May-14Presentation to University of Michigan | 19-May-14
Presentation to University of Michigan | 19-May-14
 
DuPont packaging awards May 2014
DuPont packaging awards May 2014DuPont packaging awards May 2014
DuPont packaging awards May 2014
 
ColaLife presention to C2MTL | 28-May-2014
ColaLife presention to C2MTL | 28-May-2014ColaLife presention to C2MTL | 28-May-2014
ColaLife presention to C2MTL | 28-May-2014
 
What we've learnt from Coca-Cola | Taking ColaLife to scale in Zambia
What we've learnt from Coca-Cola | Taking ColaLife to scale in ZambiaWhat we've learnt from Coca-Cola | Taking ColaLife to scale in Zambia
What we've learnt from Coca-Cola | Taking ColaLife to scale in Zambia
 
ColaLife | Key milestones - 1985 to Dec-13
ColaLife | Key milestones - 1985 to Dec-13ColaLife | Key milestones - 1985 to Dec-13
ColaLife | Key milestones - 1985 to Dec-13
 
ColaLife and frugal innovation 18-Sep-13
ColaLife and frugal innovation 18-Sep-13ColaLife and frugal innovation 18-Sep-13
ColaLife and frugal innovation 18-Sep-13
 
Presentation to the International Society for Neglected Tropical Diseases - 1...
Presentation to the International Society for Neglected Tropical Diseases - 1...Presentation to the International Society for Neglected Tropical Diseases - 1...
Presentation to the International Society for Neglected Tropical Diseases - 1...
 

Recently uploaded

Neuro Saphirex Cranial Brochure
Neuro Saphirex Cranial BrochureNeuro Saphirex Cranial Brochure
Neuro Saphirex Cranial Brochure
RXOOM Healthcare Pvt. Ltd. ​
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
The Harvest Clinic
 
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdfDemystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
SasikiranMarri
 
Essential Metrics for Palliative Care Management
Essential Metrics for Palliative Care ManagementEssential Metrics for Palliative Care Management
Essential Metrics for Palliative Care Management
Care Coordinations
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
AnushriSrivastav
 
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfCHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
Sachin Sharma
 
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
Kumar Satyam
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
Rommel Luis III Israel
 
A Community health , health for prisoners
A Community health  , health for prisonersA Community health  , health for prisoners
A Community health , health for prisoners
Ahmed Elmi
 
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfCHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
Sachin Sharma
 
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
ILC- UK
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Rommel Luis III Israel
 
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
samahesh1
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
TheDocs
 
Artificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular TherapyArtificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular Therapy
Iris Thiele Isip-Tan
 
How many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdfHow many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdf
pubrica101
 
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
The Lifesciences Magazine
 
ventilator, child on ventilator, newborn
ventilator, child on ventilator, newbornventilator, child on ventilator, newborn
ventilator, child on ventilator, newborn
Pooja Rani
 
HEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptxHEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptx
priyabhojwani1200
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Dr. David Greene Arizona
 

Recently uploaded (20)

Neuro Saphirex Cranial Brochure
Neuro Saphirex Cranial BrochureNeuro Saphirex Cranial Brochure
Neuro Saphirex Cranial Brochure
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
 
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdfDemystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
 
Essential Metrics for Palliative Care Management
Essential Metrics for Palliative Care ManagementEssential Metrics for Palliative Care Management
Essential Metrics for Palliative Care Management
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
 
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfCHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
 
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
 
A Community health , health for prisoners
A Community health  , health for prisonersA Community health  , health for prisoners
A Community health , health for prisoners
 
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfCHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
 
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
 
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
 
Artificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular TherapyArtificial Intelligence to Optimize Cardiovascular Therapy
Artificial Intelligence to Optimize Cardiovascular Therapy
 
How many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdfHow many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdf
 
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
 
ventilator, child on ventilator, newborn
ventilator, child on ventilator, newbornventilator, child on ventilator, newborn
ventilator, child on ventilator, newborn
 
HEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptxHEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptx
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
 

Shoprite launch event slidesdeck 27-Nov-15

  • 1.
  • 3. Headline findings from the Kit Yamoyo trial Sep-12 to Aug-13 14The perception of ORS as an effective treatment for diarrhoea increased by 14 percentage points. >26k kits sold into the two remote rural trial areas in 12 months. 45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%. (OR 20.4, p<0.001) 2.4km The distance to ORS/Zinc in the trial areas was reduced by two- thirds from 7.3km to 2.4km. (p<0.001) 93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets. (OR 1.84, p<0.05)
  • 4. The Mapilelo Clinic in Kalabo is a Kit Yamoyo wholesaler and retailer
  • 5. The Kit Yamoyo assembly team at Pharmanova
  • 6. Tonight’s beer and soft drinks have been provided courtesy of Zambian Breweries part of the SABMiller Group. SABMiller were partners in the Kit Yamoyo trial providing: • Advice of value chain creation • Funding and meeting facilities
  • 7. Kit Yamoyo assembly at Pharmanova
  • 8.
  • 9. Medical Stores Limited are distributing a GRZ version of the Kit Yamoyo
  • 10. Medical Stores Limited will advertise Kit Yamoyo on their vehicles
  • 11.
  • 12.
  • 13. 200ml sachets of ORS – made in Zambia • No wastage • Less risk of contamination
  • 14. Pediatric dispersible Zinc – made in Zambia
  • 15. The Kit Yamoyo Flexi-pack
  • 16. The Kit Yamoyo Flexi-pack measures the water needed to mix the ORS correctly
  • 17. The Screw-top version of Kit Yamoyo is coming soon! Made in Zambia
  • 18.
  • 19. Progress towards national scale-up Trial – Sep-12 to Sep-13 Intervention districts
  • 20. Progress towards national scale-up Control districts Trial – Sep-12 to Sep-13 Intervention districts
  • 21. Progress towards national scale-up Control districts Trial – Sep-12 to Sep-13 Transition – from Oct-13 Transition districts Intervention districts
  • 22. Progress towards national scale-up Control districts Trial – Sep-12 to Sep-13 Transition – from Oct-13 Transition districts Intervention districts Activity in Southern Province stopped in Nov-14 due to a lack of funding. We plan to re-start marketing in early 2016.
  • 23. Progress towards national scale-up Scale-up Control districts Trial – Sep-12 to Sep-13 Transition – from Oct-13 Transition districts Intervention districts KYTS-ACE – from Feb-15 Activity in Southern Province stopped in Nov-14 due to a lack of funding. We plan to re-start marketing in early 2016.
  • 24. Progress towards national scale-up Activity in Southern Province stopped in Nov-14 due to a lack of funding. We plan to re-start marketing in early 2016. Scale-up Control districts KYTS-LUSAKA – from Oct-15 Trial – Sep-12 to Sep-13 Transition – from Oct-13 Transition districts Intervention districts KYTS-ACE – from Feb-15
  • 25. Scale-up Control districts KYTS-LUSAKA – from Oct-15 Trial – Sep-12 to Sep-13 Transition – from Oct-13 Transition districts Intervention districts KYTS-ACE – from Feb-15 Progress towards national scale-up KYTS-SHOPRITE – from Dec-15 Activity in Southern Province stopped in Nov-14 due to a lack of funding. We plan to re-start marketing in early 2016.
  • 26. Tonight’s beer and soft drinks have been provided courtesy of Zambian Breweries part of the SABMiller Group. SABMiller were partners in the Kit Yamoyo trial providing: • Advice of value chain creation • Funding and meeting facilities
  • 27. Thank you to the Kit Yamoyo funders Isenberg Family Charitable Foundation

Editor's Notes

  1. This presentation describes the progress of UK charity ColaLife from its initial concept to ‘piggyback’ simple medicines, at the ‘last mile’ of distribution in developing countries, through to the results and learning from the 2-year trial in Zambia, to scale-up plans to cover the whole of Zambia and spread designs and learning more widely.
  2. However, another surprising result: shop-keepers did not find it helpful to be able to pack Kit Yamoyo into Cola crates at the point of purchase… Anyone can have access to these findings, by registering their interest with us.
  3. Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here. As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
  4. Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here. As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
  5. Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here. As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
  6. Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here. As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
  7. Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here. As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
  8. Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here. As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
  9. Thanks to DfID funding we will start scale-up where most people live - over 2 million of Zambia’s 13 million people live here. As the final step to national scale-up we will seek support to develop the market in the Copperbelt (green circle) where another 2 milllion live.
  10. It was the early commitment of funds to the ColaLife idea that leveraged all the other support for the trial and subsequent to the trial additional funders have come on-board. Notably Ceniarth and the Isenberg Family Charitable Foundation have provided ‘catalytic’ funding and we have always enjoyed support from individual supporters.